Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next
Author: Lems Three stars, 500 posts Old School Fool Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 208  
Subject: and Polysciences Inc. Date: 10/29/2001 5:04 PM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 0


October 29, 2001 16:13

QIAGEN and Polysciences Inc. Announce Alliance on Magnetic Polymer Bead Technologies
VENLO, Netherlands and WARRINGTON, Pa., Oct. 29 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA; Easdaq: QGEN) and Polysciences, Inc. announced today that they have entered into a development, supply and marketing agreement. Under the terms of the agreement QIAGEN has received exclusive rights to develop and market certain of Polysciences' existing and future magnetic polymer technologies. QIAGEN believes that Polysciences' broad technology portfolio will lead to a range of products for manual and automated separation and purification of cells and proteins and that it will significantly expand QIAGEN's current magnetic particle technology range addressing certain applications in nucleic acid purification.

QIAGEN believes that the intended magnetic particle-based products uniquely combine requirements in the rapidly growing genomics, proteomics and cellomics markets. Certain forms of cell separation and protein separation required in cellomics and proteomics are closely linked with nucleic acid purification, in both research and clinical applications. Therefore, products which link the technologies will offer significant advantages for users in these markets, who will benefit all the more because the products will be optimized to share the same QIAGEN BioRobot automation platforms. Magnetic particles are seen by QIAGEN to have applicability in certain segments of nucleic acid purification and have therefore already been one of many technologies incorporated in the broad portfolio of QIAGEN nucleic acid purification products today.

QIAGEN intends to launch the first products resulting from this alliance in the second quarter of 2002. These intended first products will primarily address several applications in cell separation and will also include products for the separation and purification of nucleic acids and proteins. Under the terms of the agreement, Polysciences is to receive approximately $0.8 million in cash and approximately 52 thousands shares of restricted common stock in QIAGEN N.V. in exchange and in consideration for the transfer of certain assets.

"We are very impressed by the depth of polymer chemistry technology and expertise at Polysciences. This perfectly complements QIAGEN's technology focus," said Dr. Ulrich Schriek, QIAGEN's Vice President for Corporate Business Development. "The exclusive nature of this agreement allows QIAGEN to access Polysciences' substantial research and manufacturing strength with the goal of unleashing the benefits of magnetic polymers in applications requiring the moving or purifying biological samples using magnetic forces. We also look forward to working with Polysciences on research and development programs on new applications for our customer base. Their customers include many names in health care and other fields. With this alliance, we believe that Polysciences' technologies will soon be incorporated into a number of QIAGEN's market and technology leading products used in the handling, separation and purification of biomolecules."

"Polysciences looks forward to a mutually beneficial relationship in this specific particle area and other future endeavors with QIAGEN," said Mr. Michael Ott, CEO of Polysciences, Inc. "Polysciences brings its 40 years of experience in the specialty monomer, polymer, and particle areas together with Qiagen's extensive technical and marketing expertise in innovative biotechnology, to further help supply novel solutions to scientists around the world."

About QIAGEN N.V.

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,500 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com.

About Polysciences, Inc.

Polysciences Inc. is dedicated to addressing its leading chemistry competence to supplying products, services, and manufacturing. The Company's business can be segmented into three categories. The laboratory products category includes catalog sales of fine chemicals, certified & fluorescent dyes, electrophoresis reagents, histology & microscopy products, microspheres & particles, polymers & monomer, and other products for industrial users and scientists. In the areas of Custom Synthesis and Contract Manufacturing & Formulation, Polysciences offers the custom design of materials to suit specialized needs and an extensive array of FDA and GMP compliant manufacturing services. Operating out of facilities in Warrington, PA, and Eppelheim, Germany, privately held Polysciences, Inc. employs over 90 people, most of which are scientists. Further information can be found at http://www.polysciences.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

Contacts:

Peer M. Schatz
Chief Financial Officer
QIAGEN N.V.
+49 (0)2103 29 11702
e-mail: p.schatz@de.QIAGEN.com

Dr. Solveigh Mahler
Manager Investor Relations
QIAGEN N.V.
+49 (0)2103 29 11710
e-mail: s.maehler@de.QIAGEN.com

Noonan Russo Communications
Veronica Sellar
+44 (0)20 7726 4452
Mary Claire Duch
+1 (212) 696 4455

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X12868179

SOURCE QIAGEN N.V. and Polysciences, Inc.

-0- 10/29/2001

/CONTACT: Peer M. Schatz, Chief Financial Officer, +49

-0-2103-29-11702, p.schatz@de.QIAGEN.com, or Dr. Solveigh Mahler, Manager Investor Relations, +49

-0-2103-29-11710, s.maehler@de.QIAGEN.com, both of QIAGEN N.V.; or Veronica Sellar, +44
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next

Announcements

Pencils of Promise - Back to School Drive
"Pencils of Promise works with communities across the globe to build schools and create programs that provide education opportunities for children."
Post of the Day:
Macro Economics

Ringing the NASDAQ Bell
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement